Journal News

MCP: Predicting when blood goes bad

John Arnst
March 1, 2017

Despite the best efforts of blood banks and networks, some blood bags end up spoiling before they can make it to patients in need. A blood bag’s spoilage depends on the red blood cells’ ability to avoid hemolysis caused by low ATP levels. The breaking of red blood cells can release byproducts, such as iron and hemoglobin, that become toxic in a free-floating form by intensifying bacterial infections and interfering with the nitric oxide signaling that is key for vasodilation.

IMAGE COURTESY OF ERIN WEISENHORN

In a paper published in the journal Molecular & Cellular Proteomics, researchers at the University of Wisconsin–Madison have generated a model for predicting post-storage ATP levels in blood based on the concentrations of five key metabolic factors. They found these factors exhibited high heritability and were inherited as a block rather than individually.

“We can use this model to identify blood that can be potentially stored for longer or shorter periods as well as potentially identify other factors to make all blood store longer,” says Erin M. M. Weisenhorn. Weisenhorn, the first author on the paper, is a graduate student in Joshua J. Coon’s group.

To generate this model, the researchers performed a comprehensive metabolomics and proteomics study to examine heritability of metabolites associated with ATP consumption in the red blood cells in 18 pairs of twins. Heritability is the proportion of phenotypic variability due to genetic factors.

The researchers wanted to examine the proteins in the red blood cells’ membranes because of their high abundance there. To do this, they centrifuged the hemoglobin out of whole red blood cells, as it makes up about 98 percent of the cells’ protein content. The researchers digested the remaining proteins with trypsin and subjected them to a novel proteomics and metabolomics approach. The approach involved two sets of liquid chromatography with tandem mass spectrometry, separately optimized for acidic and basic metabolites, combined with a standard analysis by gas chromatography and mass spectrometry. They quantified 328 separate metabolites from the red blood cells, including those from the glycolysis and pentose phosphate pathway.

The researchers then identified 119 membrane proteins and 148 metabolite concentrations that had a heritability rate of more than 30 percent, which previously had been established as a benchmark level of heritability in studies with the same group of twins.

The researchers additionally found that there was a 60 to 90 percent chance of heritability for the entire set of metabolites related to the pathways. “We observe that you don’t just sort of randomly inherit high levels of 2, 3-diphosphoglycerate or pyruvate, but rather that the entire block of metabolites from the intermediate part of the pathway are all inherited at a higher or lower level,” says Thomas J. Raife, a co-author at the UW’s department of pathology and laboratory medicine. “This means a phenotype.”

The researchers proposed phenotypes for both high and low levels of ATP after six weeks of storage. The phenotypes correlated to five key parameters, which include pH and concentrations of phosphofructokinase, an essential enzyme in glycolysis, as well as the proteins Band 3, BPGM and CA1. As a trio, the latter proteins correlated negatively with post-storage ATP conditions, making lower concentrations desirable for blood viability.

This phenotypic existence of varying levels of glycolysis also could have implications for a variety of metabolic diseases, says Weisenhorn. One such correlation is the Warburg effect, in which a cancer is associated with extremely elevated levels of glycolysis. “You can potentially imagine if someone inherits higher levels of these glycolytic proteins or metabolites and has naturally higher flux through this pathway, then they might be more predisposed towards cancer.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
John Arnst

John Arnst was a science writer for ASBMB Today.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Spider-like proteins spin defenses to control immunity
News

Spider-like proteins spin defenses to control immunity

Oct. 17, 2025

Researchers from Utrecht University discovered two distinct binding modes of a spider-shaped immune inhibitor found in serum.

A biological camera: How AI is transforming retinal imaging
Feature

A biological camera: How AI is transforming retinal imaging

Oct. 15, 2025

AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
Essay

AI in the lab: The power of smarter questions

Oct. 14, 2025

An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Feature

Training AI to uncover novel antimicrobials

Oct. 9, 2025

Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.

AI-designed biomarker improves malaria diagnostics
Journal News

AI-designed biomarker improves malaria diagnostics

Oct. 8, 2025

Researchers from the University of Melbourne engineered Plasmodium vivax diagnostic protein with enhanced yield and stability while preserving antibody-binding, paving the way for more reliable malaria testing.

Matrix metalloproteinase inhibitor reduces cancer invasion
Journal News

Matrix metalloproteinase inhibitor reduces cancer invasion

Oct. 8, 2025

Scientists at the Mayo Clinic engineered a TIMP-1 protein variant that selectively inhibits MMP-9 and reduces invasion of triple-negative breast cancer cells, offering a promising tool for targeted cancer research.